A Phase 1/2 Trial of VX-522 in People with Cystic Fibrosis
Phase 1/2
39
about 4.2 years
18–65
24 sites in AL, CA, CO +15
What this study is about
Researchers are testing the safety and how well a treatment called VX-522 works in people with cystic fibrosis who haven't responded to other treatments. The trial will last for about 1535 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IVA
- 2.Take VX-522 mRNA therapy
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Secondary: MAD: Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1), MAD: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Respiratory